David Wildes

2.1k total citations
24 papers, 335 citations indexed

About

David Wildes is a scholar working on Molecular Biology, Oncology and Biotechnology. According to data from OpenAlex, David Wildes has authored 24 papers receiving a total of 335 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 9 papers in Oncology and 4 papers in Biotechnology. Recurrent topics in David Wildes's work include Protein Tyrosine Phosphatases (8 papers), Signaling Pathways in Disease (7 papers) and Peptidase Inhibition and Analysis (6 papers). David Wildes is often cited by papers focused on Protein Tyrosine Phosphatases (8 papers), Signaling Pathways in Disease (7 papers) and Peptidase Inhibition and Analysis (6 papers). David Wildes collaborates with scholars based in United States. David Wildes's co-authors include James A. Wells, Mallika Singh, Jacqueline A.M. Smith, Adrian L. Gill, Elena S. Koltun, Christopher J. Schulze, Robert J. Nichols, Elsa Quintana, Mark A. Goldsmith and Tiffany J. Choy and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

David Wildes

23 papers receiving 331 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Wildes United States	10	241	156	81	37	36	24	335
Martine Darwish United States	9	232 1.0×	173 1.1×	98 1.2×	30 0.8×	14 0.4×	16	444
Sofia Cotton Portugal	10	191 0.8×	65 0.4×	88 1.1×	54 1.5×	30 0.8×	14	304
Sarah Penny United Kingdom	7	176 0.7×	89 0.6×	134 1.7×	16 0.4×	39 1.1×	13	276
Shuang Zhou China	7	121 0.5×	150 1.0×	124 1.5×	71 1.9×	48 1.3×	8	372
Emily J. Lelliott Australia	9	181 0.8×	195 1.3×	107 1.3×	25 0.7×	8 0.2×	10	337
Giulia Franciosa Denmark	11	252 1.0×	82 0.5×	44 0.5×	37 1.0×	87 2.4×	18	341
Andy N. Tran United States	6	206 0.9×	187 1.2×	156 1.9×	45 1.2×	21 0.6×	6	360
Robert J. Nichols United States	10	280 1.2×	94 0.6×	55 0.7×	24 0.6×	8 0.2×	22	387
Georgios Patsos Germany	10	259 1.1×	74 0.5×	116 1.4×	65 1.8×	24 0.7×	11	359
Shelly Kalaora Israel	7	265 1.1×	229 1.5×	251 3.1×	34 0.9×	9 0.3×	8	447

Countries citing papers authored by David Wildes

Since Specialization

Citations

This map shows the geographic impact of David Wildes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Wildes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Wildes more than expected).

Fields of papers citing papers by David Wildes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Wildes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Wildes. The network helps show where David Wildes may publish in the future.

Co-authorship network of co-authors of David Wildes

This figure shows the co-authorship network connecting the top 25 collaborators of David Wildes. A scholar is included among the top collaborators of David Wildes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Wildes. David Wildes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dilly, Julien, Eejung Kim, Lo Lai, et al.. (2025). Abstract 5507: Mechanisms of resistance to RAS-GTP inhibition in pancreatic cancer. Cancer Research. 85(8_Supplement_1). 5507–5507. 1 indexed citations

Seamon, Kenneth B., Sohini Chakraborty, Jim Cregg, et al.. (2024). 92 (PB080): Selective Inhibition of Active KRASG13C with RMC-8839 Reveals an Increased Dependence of Codon-13 KRAS-Mutant Cancers on Wild- Type RAS Isoforms. European Journal of Cancer. 211. 114618–114618. 1 indexed citations

Lee, Bianca J., Jim Cregg, Anne Edwards, et al.. (2024). Abstract 3340: RMC-5127, a first-in-class, orally bioavailable mutant-selective RASG12V(ON) inhibitor is central nervous system (CNS)-penetrant and demonstrates anti-tumor activity in a preclinical intracranial xenograft model. Cancer Research. 84(6_Supplement). 3340–3340. 3 indexed citations

Seamon, Kyle J., et al.. (2024). Abstract 4709: The RASMULTI(ON) inhibitor RMC-7977 blocks downstream MAPK and PI3K pathway activation in KRASG12X_mutant cancers. Cancer Research. 84(6_Supplement). 4709–4709. 1 indexed citations

Knox, John E., G. Leslie Burnett, Caroline E. Weller, et al.. (2024). Abstract ND03: Discovery of RMC-9805, an oral, covalent tri-complex KRASG12D(ON) inhibitor. Cancer Research. 84(7_Supplement). ND03–ND03. 12 indexed citations

Sastra, Stephen A., et al.. (2023). Abstract 1725: Preclinical evaluation of RM-042, an orally bioavailable inhibitor of GTP-RAS, in models of pancreatic ductal adenocarcinoma. Cancer Research. 83(7_Supplement). 1725–1725. 1 indexed citations

Cregg, Jim, Yu Chi Yang, Christopher J. Schulze, et al.. (2023). Abstract ND07: Discovery of RMC-6291, a tri-complex KRASG12C(ON) inhibitor. Cancer Research. 83(7_Supplement). ND07–ND07. 4 indexed citations

Nichols, Robert J., Yu Chi Yang, Jim Cregg, et al.. (2022). Abstract 3595: RMC-6291, a next-generation tri-complex KRASG12C(ON) inhibitor, outperforms KRASG12C(OFF) inhibitors in preclinical models of KRASG12C cancers. Cancer Research. 82(12_Supplement). 3595–3595. 27 indexed citations

Knox, John E., Jingjing Jiang, G. Leslie Burnett, et al.. (2022). Abstract 3596: RM-036, a first-in-class, orally-bioavailable, Tri-Complex covalent KRASG12D(ON) inhibitor, drives profound anti-tumor activity in KRASG12D mutant tumor models. Cancer Research. 82(12_Supplement). 3596–3596. 26 indexed citations

10.

Gustafson, W. Clay, David Wildes, Meghan A. Rice, et al.. (2022). Direct targeting of RAS in pancreatic ductal adenocarcinoma with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RAS^MULTI(ON) inhibitor.. Journal of Clinical Oncology. 40(4_suppl). 591–591. 23 indexed citations

11.

Lee, Bianca J., Sharmila Mallya, Nuntana Dinglasan, et al.. (2021). Efficacy of a Novel Bi-Steric mTORC1 Inhibitor in Models of B-Cell Acute Lymphoblastic Leukemia. Frontiers in Oncology. 11. 673213–673213. 11 indexed citations

12.

Quintana, Elsa, Christopher J. Schulze, Darienne R. Myers, et al.. (2020). Allosteric Inhibition of SHP2 Stimulates Antitumor Immunity by Transforming the Immunosuppressive Environment. Cancer Research. 80(13). 2889–2902. 69 indexed citations

13.

Myers, Darienne R., Clare L. Abram, David Wildes, et al.. (2020). Shp1 Loss Enhances Macrophage Effector Function and Promotes Anti-Tumor Immunity. Frontiers in Immunology. 11. 576310–576310. 31 indexed citations

14.

Smith, Jacqueline A.M., Mallika Singh, Robert J. Nichols, et al.. (2020). Abstract 1943: SHP2 inhibition as the backbone of targeted therapy combinations for the treatment of cancers driven by oncogenic mutations in the RAS pathway. Cancer Research. 80(16_Supplement). 1943–1943. 1 indexed citations

15.

Jiang, Jingjing, Yu Chi Yang, James Evans, et al.. (2020). Optimal therapeutic positioning of a selective bi-steric inhibitor of MTORC1 in genetically defined cancers. European Journal of Cancer. 138. S53–S53. 1 indexed citations

16.

Schulze, Christopher J., Alun Bermingham, Tiffany J. Choy, et al.. (2019). Abstract PR10: Tri-complex inhibitors of the oncogenic, GTP-bound form of KRASG12C overcome RTK-mediated escape mechanisms and drive tumor regressions in vivo. Molecular Cancer Therapeutics. 18(12_Supplement). PR10–PR10. 15 indexed citations

17.

Lee, Bianca J., Nuntana Dinglasan, G. Leslie Burnett, et al.. (2019). Abstract B108: 4EBP3 mRNA as a biomarker of therapeutic response to treatment with mTORC1 inhibitors. Molecular Cancer Therapeutics. 18(12_Supplement). B108–B108.

18.

Quintana, Elsa, Kasia Mordec, Robert J. Nichols, et al.. (2019). Abstract A103: Allosteric inhibition of SHP2 induces antitumor immunity in PD-1-sensitive tumors through modulation of both innate and adaptive mechanisms. Cancer Immunology Research. 7(2_Supplement). A103–A103. 1 indexed citations

19.

Wildes, David, Naing Aay, Ashutosh S. Jogalekar, et al.. (2018). Abstract 4877: Allosteric inhibition of SHP2 variants containing cancer-associated activating mutations. Cancer Research. 78(13_Supplement). 4877–4877. 1 indexed citations

20.

Wildes, David, et al.. (1988). VALUE ADDED DEVELOPMENTS FOR POULTRY. Journal of food distribution research. 19(1). 12–15. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact